ESBATech

ESBATech, founded in 1998 as part of the University of Zurich, is dedicated to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company utilizes its proprietary fully human single-chain antibody framework to generate candidate products targeting clinically relevant objectives. ESBATech focuses on delivering high concentrations of therapeutic antibody fragments to target sites while maintaining an extremely low systemic load, thereby achieving a low risk of systemic drug reactions through localized and targeted delivery.